UCSF Nancy Friend Pritzker Psychiatry Building
San Francisco, California, 94158, United States
Location status: Recruiting
NCT Number: NCT07579442
The goal of this clinical trial is to evaluate whether a narrative medicine (NM) curriculum can enhance self-expression, reflection, and resilience in adolescents and young adults with anorexia nervosa.
The main questions it aims to answer are:
* Does participation in an NM curriculum improve self-expression and reflection in individuals with anorexia nervosa? * Does engaging in creative writing and group discussion promote resilience and emotional processing in this population?
Participants will be 16-25 years old, medically stable for outpatient eating disorder therapy, and actively engaged in treatment. Those with active suicidal ideation, recent non-suicidal self-injury, or a co-occurring personality disorder will not be eligible.
Participants will:
* Attend six weekly workshops focused on themes such as self-definition, kindness, resilience, and possibility * Engage in close reading of visual or written texts * Complete creative writing exercises in response to prompts * Participate in group discussions and sharing
An optional capstone reading event will provide a supportive space for participants to share their work with peers, loved ones, and providers, fostering connection and community.
This study aims to explore the role of narrative medicine in eating disorder treatment and assess its potential benefits for psychological well-being and self-expression.
Interested in participating?
Request Info16 year–25 year
All sexes
Interventional
Not applicable
San Francisco, California, 94158, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Narrative Medicine (NM) Workshop Series is a structured six-week behavioral intervention designed to enhance self-expression, reflection, and resilience in adolescents and young adults recovering from eating disorders. This intervention differs from traditional psychotherapeutic or psychoeducational approaches by integrating literary analysis, creative writing, and guided discussion as therapeutic tools.
Each one-hour weekly workshop includes:
Time frame: Immediately post-intervention (Week 6)
Feasibility will be measured by participant retention in intervention.
Time frame: Immediately post-intervention (Week 6)
Acceptability will be measured by questionnaire including 5-point Likert scales and semi-structured individual interviews assessing content relevance, writing prompts, group discussions, and facilitation.
Scale title: Intervention Satisfaction Questionnaire (ISQ) Minimum value: 1 (Strongly Disagree) Maximum value: 5 (Strongly Agree) Interpretation: Higher scores indicate greater satisfaction with the intervention (better outcome).
Time frame: Pre- (Week 0) and immediately post-intervention (Week 6)
Assessed using the Illness Identity Questionnaire, which evaluates self-concept clarity and personal identity coherence.
Scale title: Illness Identity Questionnaire (IIQ) Minimum value: 1 (Strongly Disagree) Maximum value: 5 (Strongly Agree) Interpretation: Subscale scores reflect distinct illness identity states; higher scores indicate greater endorsement of that identity orientation
Time frame: Pre- (Week 0) and immediately post-intervention (Week 6)
Measured using the Social Connectedness Scale (SCS), which assesses perceived closeness to others and sense of belonging.
Scale title: Social Connectedness Scale (SCS) Minimum value: 1 (Strongly Disagree) Maximum value: 6 (Strongly Agree) Interpretation: Higher scores indicate greater feelings of social connectedness and belonging (better outcome).
Time frame: Pre- (Week 0) and immediately post-intervention (Week 6)
Measured using the Patient Health Questionnaire-9 (PHQ-9) for depressive symptoms.
Scale title: Patient Health Questionnaire-9 (PHQ-9) Minimum value: 0 (Not at all) Maximum value: 3 (Nearly every day) Interpretation: Higher scores indicate greater severity of depressive symptoms (worse outcome).
Time frame: Pre- (Week 0) and immediately post-intervention (Week 6)
Measured using the Generalized Anxiety Disorder-7 (GAD-7) for anxiety.
Scale title: Generalized Anxiety Disorder 7-item (GAD-7) Scale Minimum value: 0 (Not at all) Maximum value: 3 (Nearly every day) Interpretation: Higher scores indicate greater severity of anxiety symptoms (worse outcome).
Time frame: Pre- (Week 0) and immediately post-intervention (Week 6)
Measured using the Eating Disorder Examination Questionnaire (EDE-Q), which captures cognitive and behavioral symptoms of AN, and percent of expected body weight (EBW) at follow-up.
Scale title: Eating Disorder Examination Questionnaire (EDE-Q) Minimum value: 0 (No days / Not at all) Maximum value: 6 (Every day / Extremely) Interpretation: Higher scores indicate greater severity of eating disorder psychopathology (worse outcome).
Contact information is provided by the study sponsor or research team.
University of California, San Francisco
Other
Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07600671
Anorexia Nervosa, Binge Eating Disorder
Lebanon, New Hampshire, United States
View Trial DetailsNCT05918835
Anorexia Nervosa, Feeding and Eating Disorders
New York, United States
View Trial DetailsNCT06594913
Anorexia Nervosa, Avoidant Restrictive Food Intake Disorder
Chapel Hill, North Carolina, United States
View Trial DetailsNCT05763849
Anorexia Nervosa, Feeding and Eating Disorders
New York, United States
View Trial Details